scholarly journals Fibroblast growth factor-23 in systemic lupus erythematosus patients: Is there a correlation with interleukin-6 and left ventricular mass?

2022 ◽  
Vol 44 (3) ◽  
pp. 233-237
Author(s):  
Dina O. Abdulazim ◽  
Somaya A. Husein ◽  
Mahmoud E. Saraya ◽  
Marwa M. ElSharkawy ◽  
Ahmed Fayed ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Left Ventricular Mass ◽  
Lupus Erythematosus ◽  
Interleukin 6 ◽  
Fibroblast Growth Factor 23 ◽  
Left Ventricular ◽  
Fibroblast Growth ◽  
Systemic Lupus

scholarly journals Association of serum intact fibroblast growth factor 23 with left ventricular mass and different echocardiographic findings in patients on hemodialysis

2016 ◽  
Vol 4 (3) ◽  
pp. 135-141 ◽  
Author(s):  
Amir Ahmad Nassiri ◽  
Monir Sadat Hakemi ◽  
Reza Safar-Pour ◽  
Ali Ahmadi ◽  
Maryam Tohidi ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Left Ventricular Mass ◽  
Fibroblast Growth Factor 23 ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Fibroblast Growth ◽  
Ventricular Ejection Fraction ◽  
Ventricular Mass ◽  
Lv Mass

Abstract Objectives To determine the association of fibroblast growth factor 23 (FGF23) with left ventricular hypertrophy (LVH) through the assessment of left ventricular (LV) mass and left ventricular mass index (LVMI) in patients on hemodialysis, this study was done. Methods All patients on hemodialysis who are older than 18 years and in whom hemodialysis vintage was at least 6 months were enrolled. All patients were on hemodialysis thrice a week for 4 h using low-flux dialysis filters, polysulfone membranes, reverse osmosis purified water, and bicarbonate-base hemodialysis solution. The exclusion criteria were any respiratory illness or pulmonary infection, cigarette smoking, and the presence of pericarditis or pericardial effusion. Additionally, patients with a known coronary artery disease, any form of cardiac arrhythmias, any cardiomyopathy or severe valvular heart disease diagnosed by echocardiography, acute congestive heart failure (CHF), and acute myocardial infarction were not included. Echocardiography was conducted by an experienced operator for all the enrolled patients using the ACUSON SC2000™ ultrasound system transducer (Siemens), with a frequency bandwidth of: 1.5–3.5 MHz. Patients were considered to have LVH if the LVMI was greater than 134 g/m2 for men and greater than 110 g/m2 for women. Results A total of 61 patients (19 female and 42 male) were enrolled to the study. Mean (± SD) age of the patients was 59.6 ± 13.1 years. The median duration of hemodialysis was 23 (range: 6–120) months. The median predialysis level of FGF23 was 1,977 pg/mL (range: 155–8,870). LVH was seen in 73.8% of the patients (n = 45) and of them 66.7% were male. There was a statistically significant direct correlation between FGF23 and left ventricle diameter in end systole (LVDs) (r = 0.29, P = 0.027). However, the association of FGF23 with LV mass, LVMI, and left ventricular ejection fraction (LVEF) was not significant. Conclusion This study does not show the correlation between FGF23 and LV mass in stable hemodialysis patients.

scholarly journals The fibroblast growth factor-23/vitamin D axis, left ventricular mass and mortality in elderly people

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P634-P634
Author(s):  
S. Masson ◽  
R. Latini ◽  
G. F. Mureddu ◽  
N. Agabiti ◽  
M. Miceli ◽  
...  
Keyword(s):  
Vitamin D ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Elderly People ◽  
Left Ventricular Mass ◽  
Fibroblast Growth Factor 23 ◽  
Left Ventricular ◽  
Fibroblast Growth ◽  
Ventricular Mass
Sign in / Sign up

Export Citation Format

Share Document